ID
IONS icon

Integral Derivatives’s Ionis Pharmaceuticals IONS Stock Holding History

Integral Derivatives’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-35,300
Closed -$2.19M – 987
2015
Q4 		$2.19M Buy
35,300
+4,200
+14% +$227K 0.06% 255
2015
Q3 		$1.26M Buy
31,100
+1,600
+5% +$82.8K 0.03% 438
2015
Q2 		$1.7M Hold
29,500
– – 0.05% 366
2015
Q1 		$1.88M Hold
29,500
– – 0.04% 302
2014
Q4 		$1.82M Buy
29,500
+4,200
+17% +$207K 0.03% 471
2014
Q3 		$982K Buy
25,300
+200
+0.8% +$7.09K 0.02% 721
2014
Q2 		$865K Buy
25,100
+19,600
+356% +$617K 0.02% 743
2014
Q1 		$238K Buy
+5,500
New +$267K ﹤0.01% 1129

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Integral Derivatives's IONS Position: Q1 2016 in Review

Integral Derivatives sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 33,847 shares — an estimated $1.37M sold.

Integral Derivatives first reported a position in IONS in Q2 2014 and held it in 7 quarters. The position peaked at $2.75M in Q4 2014. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

  • Integral Derivatives reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Integral Derivatives sold 33,847 Ionis Pharmaceuticals shares in Q1 2016, an estimated $1.37M.
  • Integral Derivatives first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • Integral Derivatives's Ionis Pharmaceuticals position peaked at $2.75M in Q4 2014.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Integral Derivatives's 13F filing for Q1 2016, filed 12 Apr 2016.